Neurologix Announces First Quarter 2011 Financial Results

Friday, May 13, 2011 General News
Email Print This Page Comment
Font : A-A+

NEUROLOGIX, INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(UNAUDITED)

(Amounts in thousands, except share and per share amounts)

Three Months EndedMarch  31,

For the period February 12, 1999(inception) throughMarch 31, 2011

2011

2010

Revenues

$        -

$          -

$          -

Operating expenses:

Research and development

1,227

1,857

34,723

General and administrative expenses

830

1,284

23,044

Loss from operations

(2,057)

(3,141)

(57,767)

Other (expense) income:

Dividend, interest and other income

-

-

1,885

Interest expense – related parties

(1,368)

-

(2,234)

Change in estimated fair value of derivative financial instruments – warrants

1,343

(356)

(1,892)

 Other (expense) income, net

(25)

(356)

(2,241)

Net loss

(2,082)

(3,497)

$(60,008)

Preferred stock dividends

(828)

(771)

Net loss applicable to common stock

$(2,910)

$(4,268)

Net loss applicable to common stock per share, basic and diluted

$(0.10)

$(0.15)

Weighted average common shares outstanding, basic and diluted

27,918,148

27,865,010



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook